Gyrodyne, LLC (GYRO) · Nov 5, 2026 · Disposition

Gyrodyne annual remarks cut NAV estimate as B2K deal wobbles

NAV estimate cut — $10.75 per share vs. $12.30 at June 30, 2026

Gyrodyne’s annual remarks flag serious Flowerfield deal uncertainty, shift toward a possible New York State sale, and cut estimated liquidation value.

Gyrodyne is a liquidation-stage real-estate company trying to maximize distributions by securing entitlements and selling its two remaining properties, Flowerfield and Cortlandt Manor. That strategy was already dependent on approvals, litigation and a slow property market.

The main change is a retreat from the expected B2K route. Management now says the 49-acre Flowerfield sale to B2K faces a material risk of missing the end-2028 target—or not closing at all—because of a dispute over a visual easement. The company is instead negotiating a possible sale of the acreage to New York State, contingent on terminating the B2K agreement and likely paying B2K a significant amount.

The alternative could improve timing and execution risk, but it is not a signed transaction. Gyrodyne believes a state sale could avoid much of the sewage-treatment and infrastructure work required under the B2K plan and could close in the second half of 2027. However, both agreements remain under negotiation, the sale depends heavily on government action, and the company has not disclosed the proposed sale price or B2K termination payment.

The immediate economic read-through is negative: liquidation value was marked down materially. The preliminary estimate of net assets in liquidation fell to $10.75 per share from $12.30 at June 30, primarily because the estimated state-sale outcome, after termination costs, is worth less than the prior B2K scenario.

Cost control helps, but does not offset the asset-value reset. Cutting the workforce to one full-time employee and managing Westchester internally should save about $620,000 over the remaining liquidation period, while first-half costs exceeded receipts by $677,000, only modestly better than a year earlier. The sharper issue is that occupancy fell to 80%, and Cortlandt Manor’s redevelopment plan is being reconsidered because expected medical-office demand is below the permitted scale.

Financing has been extended, but at a higher cost. The Cortlandt Manor loan was extended for five years after a roughly $431,000 principal paydown, with the remaining balance fixed at 7.28% versus 3.75% previously. The separate $1.5 million term loan carries 15% interest-only financing through its extension. This buys time for the liquidation plan but raises the cost of waiting.

Bottom line: The filing exposes a weaker and more uncertain Flowerfield sale path, with a meaningful reduction in estimated liquidation value. The possible state transaction may be a faster, cleaner route, but until it is signed, the business story has deteriorated rather than been repaired.

What to watch next

New York State sale and B2K termination agreements

Original filing on SEC EDGAR

More Gyrodyne, LLC news

• Gyrodyne debt refinancing extends runway but resets rate higher